Literature DB >> 16596794

Human studies of cannabinoids and medicinal cannabis.

P Robson1.   

Abstract

Cannabis has been known as a medicine for several thousand years across many cultures. It reached a position of prominence within Western medicine in the nineteenth century but became mired in disrepute and legal controls early in the twentieth century. Despite unremitting world-wide suppression, recreational cannabis exploded into popular culture in the 1960s and has remained easily obtainable on the black market in most countries ever since. This ready availability has allowed many thousands of patients to rediscover the apparent power of the drug to alleviate symptoms of some of the most cruel and refractory diseases known to humankind. Pioneering clinical research in the last quarter of the twentieth century has given some support to these anecdotal reports, but the methodological challenges to human research involving a pariah drug are formidable. Studies have tended to be small, imperfectly controlled, and have often incorporated unsatisfactory synthetic cannabinoid analogues or smoked herbal material of uncertain composition and irregular bioavailability. As a result, the scientific evaluation of medicinal cannabis in humans is still in its infancy. New possibilities in human research have been opened up by the discovery of the endocannabinoid system, a rapidly expanding knowledge of cannabinoid pharmacology, and a more sympathetic political environment in several countries. More and more scientists and clinicians are becoming interested in exploring the potential of cannabis-based medicines. Future targets will extend beyond symptom relief into disease modification, and already cannabinoids seem to offer particular promise in the treatment of certain inflammatory and neurodegenerative conditions. This chapter will begin with an outline of the development and current status of legal controls pertaining to cannabis, following which the existing human research will be reviewed. Some key safety issues will then be considered, and the chapter will conclude with some suggestions as to future directions for human research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596794     DOI: 10.1007/3-540-26573-2_25

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  15 in total

1.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

3.  Cannabinoid pharmacology: the first 66 years.

Authors:  Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.

Authors:  Natasha T Snider; Vyvyca J Walker; Paul F Hollenberg
Journal:  Pharmacol Rev       Date:  2010-02-04       Impact factor: 25.468

5.  Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.

Authors:  John Merrick; Brian Lane; Terri Sebree; Tony Yaksh; Carol O'Neill; Stan L Banks
Journal:  Cannabis Cannabinoid Res       Date:  2016-04-01

6.  Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.

Authors:  David S Jacobs; Stephen J Kohut; Shan Jiang; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman
Journal:  Exp Clin Psychopharmacol       Date:  2016-08-15       Impact factor: 3.157

Review 7.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 8.  The neurobiology of individual differences in complex behavioral traits.

Authors:  Ahmad R Hariri
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

9.  Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function.

Authors:  Ahmad R Hariri; Adam Gorka; Luke W Hyde; Mark Kimak; Indrani Halder; Francesca Ducci; Robert E Ferrell; David Goldman; Stephen B Manuck
Journal:  Biol Psychiatry       Date:  2008-12-21       Impact factor: 13.382

Review 10.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.